Tennessee Oncology

Tennessee Oncology Offers Mesothelioma Expertise

Tennessee Oncology gives patients throughout the region access to clinical expertise and high-quality cancer care in convenient locations.

Through this networking relationship, specialists share scientific advancements and cutting-edge research, often leading to better cancer-care outcomes.

Patients with mesothelioma may not have to travel far to find multidisciplinary treatment. More than 30 Tennessee Oncology locations provide on-site chemotherapy treatment, which is a major part of the standard-of-care for mesothelioma.

“The size, strength and depth of our organization gives our patients a tremendous advantage, from diagnosis, to symptom management, to the latest treatments and clinical trials,” said medical oncologist Dr. B. Stephens Dudley.

In 2018, Tennessee Oncology joined forces with OneOncology, a nationwide partnership of leading independent oncology practices, adding to the strength and expertise of the program.

Access to Innovation at Tennessee Oncology

Tennessee Oncology also has access to the Sarah Cannon Research Institute, which includes a clinical trial network as vast as any in the country. Sarah Cannon has been involved in many of the new cancer therapy approvals throughout the past decade.

Medical oncologists Dr. David Spigel, Dr. E. Kirk Barnes, Dr. William Liggett and Dr. Michel Kuzur are spread across the Nashville area and involved in the treatment of mesothelioma and lung cancer.

Depending on the stage and type of cancer diagnosed, treatment at Tennessee Oncology is personalized to meet each patient’s needs.

Tennessee Oncology prides itself on being a patient-centered practice with a caring, community environment. A patient’s care team could include a nurse practitioner, a health psychologist, a support specialist and a financial counselor, as well as medical specialists.

Treatment could include surgery, radiation, chemotherapy, immunotherapy, vaccines and follow-up maintenance therapy. It also could include enrollment in a clinical trial, where the latest therapeutic advancements could be found.

“Our group is always ahead of the curve in treatment outcome,” said medical oncologist Dr. Victor Gian. “Early on, we saw the benefit of clinical research to our patients. We believe and practice innovation.”

Mesothelioma Clinical Trials at Tennessee Oncology

• A phase I/II clinical trial studying the effectiveness of the drug INCAGN01876, which helps activate the immune system, when used in combination with nivolumab (Opdivo) and ipilimumab (Yervoy) in metastatic malignancies, including mesothelioma.
• A phase II clinical trial designed to establish recommended dosage levels for genetically engineered T-cells used to fight cancers expressing high levels of mesothelin, which often includes mesothelioma.

Top